Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Closing in on a likely approval to treat retinal vein occlusion (RVO), Roche has presented long-term data that show Vabysmo can maintain visual gains in the indication with a dosing duration stretched for some patients to as long as once every four months.